t(14;16)多发性骨髓瘤223例多中心回顾性研究
这项国际多中心回顾性研究纳入223例t(14;16)多发性骨髓瘤患者,24%初诊伴肾功能不全,56%血红蛋白<10 g/dL。中位随访4.1年,中位无进展生存期2.1年、总生存期4.1年;年龄>60岁和R-ISS 3是总生存期的不良预测因素。
要点
- t(14;16)骨髓瘤患者初诊时常见肾功能不全和贫血。
- 中位无进展生存期2.1年,中位总生存期4.1年。
- 年龄>60岁和R-ISS 3提示总生存期更差。
核心结论
- 在目前最大t(14;16)骨髓瘤队列中,约四分之一患者初诊伴肾功能不全,高龄和R-ISS 3预测总生存期不良。
研究设计与样本
- 国际多中心(25个中心)回顾性研究,纳入223例t(14;16)多发性骨髓瘤患者。
主要发现
- 初诊时24%患者有肾功能不全,56%患者血红蛋白<10 g/dL。
- 一线联合免疫调节药物和蛋白酶体抑制剂者占35%,42%患者接受自体造血干细胞移植。
- 中位随访4.1年(95% CI 3.7-18.7),中位无进展生存期2.1年(95% CI 1.5-2.4),中位总生存期4.1年(95% CI 3.3-5.5)。
- 年龄>60岁预测更差总生存期(HR=1.65,95% CI 1.05-2.58),R-ISS 3较R-ISS 2预测更差总生存期(HR=2.59,95% CI 1.59-4.24)。
临床怎么用
- 对t(14;16)骨髓瘤患者应关注初诊肾功能和贫血评估。
- 高龄和R-ISS 3患者可考虑更密切监测和个体化治疗。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The t(14;16) translocation, found in 3%-5% of newly diagnosed (ND) multiple myeloma (MM), has been associated with adverse outcomes. However, the studies establishing the characteristics of t(14;16) included solely small cohorts. The goal of the current international, multicenter (n = 25 centers), retrospective study was to describe the characteristics and outcomes of t(14;16) patients in a large, real-world cohort (n = 223). A substantial fraction of patients had renal impairment (24%) and hemoglobin <10 g/dL (56%) on initial presentation. Combined therapy of both immunomodulatory drug and proteasome inhibitor (PI) in the first line was used in 35% of patients. Autologous stem cell transplantation was performed in 42% of patients. With a median follow up of 4.1 years (95% CI 3.7-18.7), the median progression-free survival (PFS) and overall survival (OS) from first line therapy were 2.1 years (95% CI 1.5-2.4) and 4.1 years (95% CI 3.3-5.5), respectively. Worse OS was predicted by age > 60 years (HR = 1.65, 95% CI [1.05-2.58]), as well as revised International Scoring System (R-ISS) 3 (vs R-ISS 2; HR = 2.59, 95% CI [1.59-4.24]). In conclusion, based on the largest reported cohort of t(14;16) patients, quarter of this subset of MM patients initially presents with renal failure, while older age and the R-ISS 3 predict poor survival.
引用
- Goldman-Mazur S, Jurczyszyn A, Castillo JJ, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020. PMID: 32072687. doi:10.1002/ajh.25758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。